Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Combination inhibition of the renin-angiotensin system: is more better?

Krause MW, Fonseca VA, Shah SV.

Kidney Int. 2011 Aug;80(3):245-55. doi: 10.1038/ki.2011.142. Epub 2011 Jun 1. Review.

3.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
4.
5.
6.

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.

Tsouli SG, Liberopoulos EN, Kiortsis DN, Mikhailidis DP, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):1-15. Review.

PMID:
16703216
7.

Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.

Bomback AS, Toto R.

Am J Hypertens. 2009 Oct;22(10):1032-40. doi: 10.1038/ajh.2009.138. Epub 2009 Aug 6. Review.

PMID:
19661925
8.

Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.

Borghi C; SIIA Task Force, Rossi F; SIF Task Force.

High Blood Press Cardiovasc Prev. 2015 Dec;22(4):429-44. doi: 10.1007/s40292-015-0120-5. Epub 2015 Sep 24. Review. Erratum in: High Blood Press Cardiovasc Prev. 2016 Mar;23(1):65.

PMID:
26403596
9.

Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?

Chen SS, Seliger SL, Fried LF.

Curr Opin Nephrol Hypertens. 2014 Sep;23(5):449-55. doi: 10.1097/MNH.0000000000000043. Review.

PMID:
25014549
10.

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

Weir MR, Rolfe M.

Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48. doi: 10.2215/CJN.07821109. Epub 2010 Feb 11. Review.

11.

Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.

Tylicki L, Lizakowski S, Rutkowski B.

J Nephrol. 2012 Nov-Dec;25(6):900-10. doi: 10.5301/jn.5000134. Review.

PMID:
22684647
12.

Dual blockade of the renin-angiotensin system for cardiorenal protection: an update.

Arici M, Erdem Y.

Am J Kidney Dis. 2009 Feb;53(2):332-45. doi: 10.1053/j.ajkd.2008.11.021. Review.

PMID:
19166800
13.

Rationale for combining blockers of the renin-angiotensin system.

Azizi M, Wuerzner G.

Semin Nephrol. 2007 Sep;27(5):544-54. Review.

PMID:
17868792
14.

On target to dual block RAS?

Papadopoulos DP, Papademetriou V, Makris TK.

Angiology. 2009 Dec-2010 Jan;60(6):739-49. doi: 10.1177/0003319708329799. Epub 2009 Jan 13. Review.

PMID:
19144653
15.

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3. Review.

PMID:
18454336
16.

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.

Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908. Epub 2009 Mar 4. Review.

18.

Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.

Turgut F, Balogun RA, Abdel-Rahman EM.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1330-9. doi: 10.2215/CJN.08611209. Epub 2010 May 24. Review.

19.

Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?

Chaudhary K, Nistala R, Whaley-Connell A.

Curr Hypertens Rep. 2009 Oct;11(5):375-81. Review.

PMID:
19737455
20.

Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.

Slagman MC, Navis G, Laverman GD.

Curr Opin Nephrol Hypertens. 2010 Mar;19(2):140-52. doi: 10.1097/MNH.0b013e3283361887. Review.

PMID:
20051849

Supplemental Content

Support Center